Cytokinetics FDA approval marks a milestone with Myqorzo, challenging Bristol Myers’ Camzyos in the heart drug market.
Author: PharmaSignal News Desk
Merck and Daiichi Sankyo’s I-DXd trial faces FDA hold due to unexpected death rates in small cell lung cancer study.
BioMarin Amicus acquisition for $4.8B adds a late-stage asset and two marketed therapies generating $450M in nine months.
Novo Nordisk FDA approval for oral Wegovy marks a significant step in the obesity drug market, outpacing competitors.
Biopharma CEO optimism varies globally, with US executives showing less confidence. Survey reveals differences in outlook.
Drug price deals with Trump involve 9 drugmakers, impacting tariffs and benefits. Analysts see limited financial effect.
Aktis IPO Filing comes as the biotech sector shows signs of recovery, raising hopes for a rebound in IPO activity in 2025.
Welcome to this edition of the PharmaSignal Weekly Brief – Global Pharma Roundup. This week’s dominant themes include major M&A activity, significant regulatory approvals and strategic R&D developments. Looking ahead, we delve into the strategic implications of these events. M&A and Strategic Deals BioMarin acquired Amicus in a deal worth $4.8 billion, marking a major move in the biotech sector. Read more → Xoma strategically acquired Generation Bio, signaling a significant shift in their business model. Read more → Mirum acquired Bluejay for $620M, gaining a promising hepatitis D drug in the process. Read more → Regulatory and Approvals Cytokinetics…
Welcome to this week’s PharmaSignal Weekly Brief – Global Pharma Roundup. This week, we have seen significant movement in the M&A landscape, with major deals reshaping the biotech and rare disease sectors. Meanwhile, the FDA has been active in granting approvals and fast passes, potentially altering the competitive dynamics in several therapy areas. In the R&D space, promising trial results and strategic funding rounds have made headlines, while policy signals and market trends continue to shape the global pharma landscape. M&A and Strategic Deals BioMarin has acquired Amicus in a $4.8 billion deal, strengthening its rare disease portfolio and expanding…
Cytokinetics FDA approval marks its first drug clearance, challenging Bristol Myers’ Camzyos in the heart drug market.